Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan 21;7(1):34-37.
doi: 10.1016/j.jaccao.2024.12.001. eCollection 2025 Jan.

Heart Failure Post-Hematopoietic Cell Transplantation in Patients With Lymphoma: Another Piece of the CHIP Puzzle

Affiliations
Editorial

Heart Failure Post-Hematopoietic Cell Transplantation in Patients With Lymphoma: Another Piece of the CHIP Puzzle

Oscar Calvillo-Argüelles et al. JACC CardioOncol. .
No abstract available

Keywords: CHIP; autologous hematopoietic cell transplantation; biomarkers; heart failure; lymphoma; non-relapse mortality.

PubMed Disclaimer

Conflict of interest statement

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
Figure 1
Figure 1
An Overview of the Relevance of CHIP Based on Malignancy Type This figure provides an overview of clonal hematopoiesis of indeterminate potential (CHIP)-related cardiovascular and hemato-oncological risk in cancer patients. AML = acute myeloid leukemia; ASCVD = atherosclerotic cardiovascular disease; CAR-T = chimeric antigen receptor T-cell; CHIP-r = clonal hematopoiesis of indeterminate potential–related; CLL = chronic lymphocytic leukemia; CRS = cytokine release syndrome; CV = cardiovascular; DCL = donor cell leukemia; DDR = DNA damage-response; GVHD = graft vs host disease; HCT = hematopoietic cell transplantation; HF = heart failure; HL = Hodgkin lymphoma; MDS = myelodysplastic syndrome; m-CHIP = myeloid clonal hematopoiesis of indeterminate potential; MDS/MPN = myelodysplastic/myeloproliferative neoplasm; MM = multiple myeloma; MPN = myeloproliferative neoplasm; NGS = next-generation sequencing; NHL = non-Hodgkin lymphoma; NRM = non-relapse mortality; t-MN = therapy-related myeloid neoplasm(s).

Comment on

  • doi: 10.1016/j.jaccao.2024.10.006

Similar articles

References

    1. Jaiswal S., Fontanillas P., Flannick J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–2498. - PMC - PubMed
    1. Weeks L.D., Ebert B.L. Causes and consequences of clonal hematopoiesis. Blood. 2023;142:2235–2246. - PMC - PubMed
    1. Schuermans A., Honigberg M.C., Raffield L.M., et al. Clonal hematopoiesis and incident heart failure with preserved ejection fraction. JAMA Netw Open. 2024;7 - PMC - PubMed
    1. Bolton K.L., Gillis N.K., Coombs C.C., et al. Managing clonal hematopoiesis in patients with solid tumors. J Clin Oncol. 2019;37(1):7–11. doi: 10.1200/JCO.18.00331. - DOI - PMC - PubMed
    1. Calvillo-Argüelles O., Schoffel A., Capo-Chichi J.M., et al. Cardiovascular disease among patients with AML and CHIP-related mutations. J Am Coll Cardiol CardioOnc. 2022;4:38–49. - PMC - PubMed

Publication types

LinkOut - more resources